RAPP News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

RA

Mkt Cap

$1.32B

Volume

307.04K

Next Earnings

November 5th

Loading chart

RA

RAPPRapport Therapeutics, Inc. Common Stock

RAPP

Pay with—

Available Balance0.00

RA

Mkt Cap

$1.42B

Volume

307.04K

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and VaxcyteFour biotech companies—Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics, and Vaxcyte—are approaching significant clinical trial readouts in fall 2026 that could materially impact their valuations. Kodiak will report phase III data for wet AMD treatments, Celldex expects CSU study results, Rapport targets bipolar mania trial outcomes, and Vaxcyte will release pneumococcal vaccine data. These mid- to late-stage readouts represent major catalysts for clinical-stage companies.Zacks Investment Research · Sep 23, 2026

Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual MeetingRapport Therapeutics announced it will present Phase 2a trial results for RAP-219, a potential first-in-class AMPA receptor negative allosteric modulator, at the 2026 American Academy of Neurology Annual Meeting in Chicago on April 21. The presentation will include new 8-week follow-up data on efficacy and tolerability in focal onset seizure patients. RAP-219 is being evaluated for multiple neurological and psychiatric indications including seizures, bipolar disorder, and neuropathic pain.GlobeNewswire Inc. · Apr 1, 2026

Rapport Announces Pricing of Public Offering of Common StockRapport Therapeutics announced a public offering of 9,615,385 shares of common stock at $26.00 per share, expecting to raise approximately $250 million. The offering is expected to close on September 11, 2025, with Goldman Sachs, Jefferies, TD Cowen, and Stifel acting as joint book-running managers.Benzinga · Sep 10, 2025

Analysts Can't Get Enough of These Little-Known Biopharma StocksAnalysts are bullish on several little-known biopharma stocks, including Kymera Therapeutics, Vera Therapeutics, and Rapport Therapeutics, due to promising drug candidates and strong financial positions.Investing.com · Jun 12, 2025

Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate UpdatesRapport Therapeutics announced that its Phase 2a trial of RAP-219 for refractory focal epilepsy is fully enrolled and on track to report topline results in September 2025. The company also provided updates on the RAP-219 development program and its financial position.GlobeNewswire Inc. · Jun 2, 2025

Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual MeetingRapport Therapeutics, a clinical-stage biotechnology company, announced two encore poster presentations at the 2025 AAN Annual Meeting. The presentations will highlight the company's ongoing research and development of RAP-219, a clinical-stage AMPA receptor negative allosteric modulator, for the treatment of refractory focal epilepsy.GlobeNewswire Inc. · Mar 21, 2025

Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS DisordersRapport Therapeutics announced positive results from its Phase 1 trials for RAP-219, a potential treatment for central nervous system disorders. The data showed that RAP-219 achieved target receptor occupancy and was generally well-tolerated, supporting its ongoing Phase 2a trial in focal epilepsy.GlobeNewswire Inc. · Jan 9, 2025

Rapport Therapeutics to Present at Upcoming Epilepsy Medical ConferencesRapport Therapeutics, a clinical-stage biotechnology company, announced that it will present on its lead product candidate RAP-219 at two upcoming medical conferences focused on epilepsy. The presentations will cover the novel design of a Phase 2a proof-of-concept trial for RAP-219 in patients with drug-resistant focal epilepsy, as well as the underlying mechanism of action.GlobeNewswire Inc. · Sep 5, 2024

Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen’s 4th Annual Novel Mechanisms in Neuropsychiatry SummitRapport Therapeutics, a clinical-stage biotechnology company, announced that it will present at the Morgan Stanley Global Healthcare Conference and the TD Cowen's Novel Mechanisms in Neuropsychiatry Summit. The company is focused on developing small molecule medicines for central nervous system disorders.GlobeNewswire Inc. · Aug 29, 2024

Wall Street Breakfast: The Week AheadStay up to date on Wall Street news with our daily podcast available on Seeking Alpha, iTunes, and Spotify.Seeking Alpha · Jun 30, 2024

to start trading

RA

RAPPRapport Therapeutics, Inc. Common Stock

RAPP

Pay with—

Available Balance0.00

Your PositionYou don't own any RAPP yet.

Related Tickers

Earnings